Vaccine News and Research

Latest Vaccine News and Research

AFP examines recent HIV vaccine findings

Agence France-Presse examines how two recent studies have "boosted morale" among HIV vaccine researchers who have struggled for decades to develop a viable vaccine to protect people from the virus. "On September 3, researchers in the United States discovered two potent antibodies -- the frontline troops in the immune system -- that expose what may prove to be a viral Achilles' heel," the news service writes.

22 Oct 2009

FMWC partners with SOGC and SCC to launch Pap test campaign

The Federation of Medical Women of Canada (FMWC) has joined forces with the Society of Obstetricians and Gynaecologists of Canada (SOGC) and the Society of Canadian Colposcopists (SCC) to launch this year's Pap test campaign during Cervical Cancer Awareness Week. Together, we hope to increase the scope, reach and impact of the campaign. With this collaborative effort, we aim to provide more Pap tests and deal with abnormal results in a more expeditious manner.

22 Oct 2009

Merck's sales increases by 2% in third quarter 2009

Merck & Co., Inc. today announced financial results for the third quarter of 2009. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the quarter of $0.90, which excludes a $1.7 billion after-tax gain from the sale of the company's interest in Merial Limited as well as restructuring charges and pre-closing merger-related expenses. Third-quarter GAAP EPS was $1.61.

22 Oct 2009

Schering-Plough announces 2009 third quarter financial results

Schering-Plough Corporation (NYSE: SGP) today reported financial results for the 2009 third quarter.

22 Oct 2009

Sartorius reports financial results for the third quarter of 2009

Today Sartorius, a leading international process and laboratory technology provider, reported its nine-month results for 2009. Third-quarter business of both Group divisions showed a highly divergent pattern of development, similar to that in the previous quarters.

From Sartorius 22 Oct 2009

More infants are being immunized but funding gap leaves millions of children still at risk

Reversing a downward trend, immunization rates are now at their highest ever and vaccine development worldwide is booming, according to a new assessment released today by the World Health Organization (WHO), UNICEF and the World Bank.

22 Oct 2009

eHealthInsurance releases answers for FAQs on swine flu and their health insurance

eHealthInsurance (NASDAQ: EHTH) today released a list of answers to questions frequently asked from people concerned about the H1N1 virus (also called swine flu) and their health insurance, who have called into its Customer Care Center, which includes a call center staffed with licensed insurance agents. Getting answers to these questions is particularly important for high-risk individuals: pregnant women, children and seniors.

22 Oct 2009

“Sid the Science Kid” show to explain the science behind flu vaccinations

Health and Human Services Secretary Kathleen Sebelius, Education Secretary Arne Duncan, and Lisa Henson, CEO of the Jim Henson Company, will join Washington-area school children for a screening of the new “Sid the Science Kid” special episode on the flu at the U.S. Department of Education Auditorium.

22 Oct 2009

Advisory Committee on Immunization Practices supports the permissive use of GARDASIL

Merck & Co., Inc. announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) supports the permissive use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for boys and young men ages 9 to 26, which means that GARDASIL may be given to males ages 9 to 26 to reduce the likelihood of acquiring genital warts at the discretion of the patient's health care provider.

22 Oct 2009

LANL and international researchers propose new genome sequence strategies

A team of geneticists at Los Alamos National Laboratory, together with a consortium of international researchers, has recently proposed a set of standards designed to elucidate the quality of publicly available genetic sequencing information.

22 Oct 2009

Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab

Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.

22 Oct 2009

GlaxoSmithKline's CERVARIX recommended by CDC for protection against cervical cancer

GlaxoSmithKline announced today that the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) recommended that CERVARIX® [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] be given to girls and young women to protect against cervical pre-cancers and cervical cancer caused by oncogenic HPV 16 and 18.

22 Oct 2009

Media outlets examine how AIDS vaccine trial results will shape future studies

As the AIDS vaccine conference continues in Paris this week, Reuters examines how recent trials are helping researchers better understand ways to develop a vaccine that offers people protection from HIV.

22 Oct 2009

Women more likely than men to curb swine flu

A new American Red Cross poll shows that while concerns about exposure to the H1N1 (swine flu) virus remain high, women are more likely than men to make extra efforts to cover coughs and sneezes with tissue, wash their hands more carefully and use hand sanitizer more often.

22 Oct 2009

AIDS vaccine not as effective as first thought, scientists say

A vaccine to protect against HIV may not be as effective as first thought, scientists said Tuesday.

22 Oct 2009

106m infants worldwide received vaccines last year, coverage gaps remain, report says

A joint report by the WHO, UNICEF and the World Bank on worldwide vaccination efforts released Wednesday found "a record 106 million infants were vaccinated last year against life-threatening diseases, but nearly a fifth of the world's babies still are not protected fully," the Associated Press reports.

22 Oct 2009

Research suggests latent cytomegalovirus infection exacerbates inflammatory bowel disease

Current research suggests that latent cytomegalovirus (CMV) infection may exacerbate inflammatory bowel disease (IBD). The related report by Onyeagocha et al, "Latent cytomegalovirus infection exacerbates experimental colitis," appears in the November 2009 issue of The American Journal of Pathology.

21 Oct 2009

EMEA informs Antigenics on a negative opinion for Oncophage MAA

Antigenics Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMEA), has verbally informed the Company at an oral meeting to anticipate a negative opinion on the marketing authorization application (MAA) for Oncophage (vitespen) in early-stage, localized renal cell carcinoma (kidney cancer).

21 Oct 2009

Positive results from Argos Therapeutics' personalized immunotherapy candidate AGS-004 Phase 2a trial

Argos Therapeutics today announced two presentations at the AIDS Vaccine 2009 conference, detailing positive viral load, immune response and safety data from an ongoing Phase 2a trial of AGS-004, its personalized immunotherapy candidate. AGS-004 is a product of the Company’s Arcelis™ technology, and is a personalized, RNA-loaded, dendritic cell-based immunotherapy that is perfectly matched to each patient’s unique HIV viral burden.

21 Oct 2009

Northwest Biotherapeutics announces long-term data from Phase I and Phase I/II clinical trials of DCVax-Brain

Northwest Biotherapeutics, Inc. today announced further long-term follow-up data, for the period from January through September 2009, from its prior Phase I and Phase I/II clinical trials conducted at UCLA with DCVax®-Brain in patients with Glioblastoma multiforme ("GBM"). GBM is the most rapid and lethal type of brain cancer. During the update period, only one of the twenty patients treated with DCVax®-Brain (in addition to standard of care) died, and that patient had survived for nearly 7 years (80.5 months).

21 Oct 2009

Vaccine News and Research

Latest Vaccine News and Research

AFP examines recent HIV vaccine findings

FMWC partners with SOGC and SCC to launch Pap test campaign

Merck's sales increases by 2% in third quarter 2009

Schering-Plough announces 2009 third quarter financial results

Sartorius reports financial results for the third quarter of 2009

More infants are being immunized but funding gap leaves millions of children still at risk

eHealthInsurance releases answers for FAQs on swine flu and their health insurance

“Sid the Science Kid” show to explain the science behind flu vaccinations

Advisory Committee on Immunization Practices supports the permissive use of GARDASIL

LANL and international researchers propose new genome sequence strategies

Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab

GlaxoSmithKline's CERVARIX recommended by CDC for protection against cervical cancer

Media outlets examine how AIDS vaccine trial results will shape future studies

Women more likely than men to curb swine flu

AIDS vaccine not as effective as first thought, scientists say

106m infants worldwide received vaccines last year, coverage gaps remain, report says

Research suggests latent cytomegalovirus infection exacerbates inflammatory bowel disease

EMEA informs Antigenics on a negative opinion for Oncophage MAA

Positive results from Argos Therapeutics' personalized immunotherapy candidate AGS-004 Phase 2a trial

Northwest Biotherapeutics announces long-term data from Phase I and Phase I/II clinical trials of DCVax-Brain

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Vaccine News and Research

Latest Vaccine News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in